Krebs Biochemicals Amalgamates with Ipca Laboratories in Major Strategic Merger

Krebs Biochemicals Amalgamates with Ipca Laboratories in Major Strategic Merger​

The Scheme of Amalgamation has been approved involving Krebs Biochemicals & Industries Limited, which will merge into Ipca Laboratories Limited. The merger involves the Transferor Company being absorbed by the Transferee Company. The appointed date for this Scheme is set as April 1, 2026, with operational effectiveness pending receipt of all necessary consents and approvals.

Both companies operate within the manufacturing and marketing segment of pharmaceuticals. Ipca Laboratories Limited reported an audited total income of Rs. 7431 Crores for the financial year ending March 31, 2026. In contrast, Krebs Biochemicals & Industries Limited recorded an audited total income of Rs. 26 Crores for the same period, largely derived from conversion charges received from Ipca Laboratories Limited.

The rationale behind the amalgamation centers on achieving significant operational synergies and cost optimization. The merger is designed to consolidate the business operations of both entities, leading to increased scale in the combined organization. A key strategic benefit involves transferring Krebs Biochemicals’ specialized manufacturing capabilities to Ipca Laboratories Limited. Krebs has established facilities to manufacture fermentation based Active Pharmaceutical Ingredients (APIs), a capability currently held by the Transferor Company that benefits the Transferee Company through research and commercialization of new APIs.

Furthermore, Krebs provides an uninterrupted supply chain for Ipca Laboratories Limited. Krebs manufactures one critical fermentation based API used in a major selling formulation of the Transferee Company, and it is noted that only a limited number of manufacturers globally produce this specific API. Additionally, Krebs produces several drug intermediates essential to Ipca's manufacturing processes.

The merger addresses the financial constraints faced by Krebs Biochemicals & Industries Limited, which has been continuously incurring losses and lacked the necessary financial strength to invest in research and development for new fermentation based APIs. The amalgamation with Ipca Laboratories Limited provides the stability and technical muscle required to leverage these capabilities fully.

Key details regarding the transaction are summarized below:


Regarding the consideration for this amalgamation, there is no cash consideration payable. The share exchange ratio stipulates that Ipca Laboratories Limited shall issue and allot 7 fully paid-up equity shares of Re. 1/- each for every 200 fully paid-up equity shares of Rs. 10/- held in Krebs Biochemicals & Industries Limited (excluding those held by the Transferee Company). The equity and preference shares of Krebs Biochemicals & Industries Limited held by Ipca Laboratories Limited will be cancelled and extinguished upon the Scheme's effectiveness.

The transaction, which is a merger into Ipca Laboratories Limited, means that there are no material changes to the shareholding pattern of the listed entity post-merger.

KREBSBIO Stock Price Movement​

Krebs Biochemicals and Industries Limited shares slipped by 0.03% on Thursday, closing at ₹66.24 after the trading session. The stock traded within an intraday range of ₹64.11 to ₹66.58, with 3,759 shares recorded in the transaction volume.